Related Experiment Video
Updated: May 18, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Gastrointestinal disorders and dabigatran
1I Med Clinic, Johannes Gutenberg University Mainz, Mainz, Germany. AHoff66286@aol.com
Insights
New oral anticoagulants like dabigatran etexilate offer stroke prevention for atrial fibrillation. However, this direct thrombin inhibitor may increase dyspeptic symptoms compared to warfarin.
Area of Science:
- Cardiology
- Gastroenterology
- Pharmacology
Background:
- Anticoagulants are crucial for managing thromboembolic disorders, including stroke prevention in atrial fibrillation.
- Vitamin K antagonists (VKAs) are established treatments, but new oral anticoagulants (NOACs) are emerging as alternatives.
- Dabigatran etexilate, a direct thrombin inhibitor, is increasingly recommended in guidelines for stroke prevention in atrial fibrillation.
Purpose of the Study:
- To review and discuss the potential for dabigatran etexilate to cause dyspeptic symptoms.
- To explore potential countermeasures for managing dabigatran-induced dyspepsia from a gastroenterologist's viewpoint.
Main Methods:
- Literature review of published data and clinical trial results concerning dabigatran etexilate.
- Analysis of reported side effect profiles, specifically focusing on gastrointestinal disturbances.
- Clinical perspective from gastroenterology on managing adverse effects.
Main Results:
- Published data suggest dabigatran etexilate may be associated with higher rates of dyspeptic symptoms compared to warfarin.
- Dyspepsia represents a potential side effect profile of dabigatran etexilate.
- The clinical implications of these findings require further investigation and management strategies.
Conclusions:
- Dabigatran etexilate presents a viable alternative for stroke prevention in atrial fibrillation but may be linked to increased dyspeptic symptoms.
- Gastroenterologists should be aware of this potential side effect and prepared to manage it.
- Further research and clinical guidance are needed to address dabigatran-associated dyspepsia effectively.
Abstract:
Anticoagulants play an important role in the prevention and treatment of a variety of acute and chronic thromboembolic disorders such as primary prevention and treatment of venous thromboembolism or prevention of stroke and systemic embolism in atrial fibrillation just to name of few. Within recent years, a promising new oral anticoagulant, the direct thrombin inhibitor dabigatran etexilate (dabigatran) successfully underwent clinical development and has emerged as an alternative to vitamin K antagonists according to a variety of recently revised and updated international guidelines referring to the indication of stroke prevention in atrial fibrillation. Considering the intensive clinical use of vitamin K antagonists in the mentioned indication as well as the widespread and increasing therapeutic need on one hand and the likely availability of a more efficacious alternative with fewer limitations in clinical practice on the other, there is good reason to assume that the use of dabigatran may be broad within the general medical community in the near future. Based on what is currently published in the public domain and clinical trial data it is suggested that dabigatran etexilate is associated with higher rates of dyspeptic symptoms compared to warfarin. Therefore, it is the authors' intent to review and discuss this potential dyspeptic side effect profile of dabigatran and potential counter measures from a gastroenterologist's perspective.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Other Disorders of Digestive System
Gastrointestinal Motility Disorders
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
